Sorafenib potently inhibits ETV6-PDGFRβ and FLT3 mutants, and shows activity against FLT3 mutants that are resistant to other small molecule inhibitors.

被引：1
|
作者：
Lierman, Els
Lahortiga, Idoya
Van Miegroet, Helen
Mentens, Nicole
Marynen, Peter
Cools, Jan
机构：
[1] Katholieke Univ Leuven VIB, Dept Human Genet, B-3000 Louvain, Belgium
[2] Univ Navarra, E-31080 Pamplona, Spain
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.1993.1993
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1993
引用
收藏
页码：564A / 564A
页数：1
相关论文
共 50 条
  • [1] Sorafenib potently inhibits ETV6-PDGFRβ and FLT3 mutants,and shows activity against FLT3 mutants that are resistant to other small molecule inhibitors
    Lierman, E.
    Lahortiga, I.
    Van Miegroet, H.
    Mentens, N.
    Marynen, P.
    Cools, J.
    ACTA CLINICA BELGICA, 2007, 62 (04): : 251 - 251
  • [2] The ability of sorafenib to inhibit oncogenic PDGFRβ and FLT3 mutants and overcome resistance to other small molecule inhibitors
    Lierman, Els
    Lahortiga, Idoya
    Van Miegroet, Helen
    Mentens, Nicole
    Marynen, Peter
    Cools, Jan
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 27 - 34
  • [3] Small molecule FLT3 tyrosine kinase inhibitors
    Levis, M
    Small, D
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (11) : 1183 - 1193
  • [4] HM43239, a novel FLT3 inhibitor, has the potential to inhibit mutations resistant to FLT3 inhibitors.
    Bae, Inhwan
    Choi, Jaeyul
    Song, Jiyoung
    Byun, Joo-Yun
    Lee, Eunyoung
    Song, Taehun
    Kim, Yu-Yon
    Bak, Yesol
    Kim, Young Hoon
    Ahn, Young Gil
    Suh, Kwee Hyun
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jian-kang
    Wilson, Kelli
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2015, 126 (23)
  • [6] Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
    Galanis, Allison
    Ma, Hayley
    Rajkhowa, Trivikram
    Ramachandran, Abhijit
    Small, Donald
    Cortes, Jorge
    Levis, Mark
    BLOOD, 2014, 123 (01) : 94 - 100
  • [7] Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations
    Zhang, Guo
    Zhang, Wenqing
    Shen, Chenjian
    Nan, Jinshan
    Chen, Ming
    Lai, Shusheng
    Zhong, Jiemin
    Li, Bolin
    Wang, Tianqi
    Wang, Yifei
    Yang, Shengyong
    Li, Linli
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (22)
  • [8] Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines
    Dayal, Neetu
    Opoku-Temeng, Clement
    Hernandez, Delmis E.
    Sooreshjani, Moloud Aflaki
    Carter-Cooper, Brandon A.
    Lapidus, Rena G.
    Sintim, Herman O.
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (07) : 823 - 835
  • [9] Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia – indications for an optimal dosage of inhibitors against FLT3 and CDK6
    Antoine Buetti-Dinh
    Ran Friedman
    BMC Bioinformatics, 19
  • [10] BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors
    Rodriguez, Melissa
    Fiskus, Warren
    Sharma, Sunil
    Qi, Jun
    Schaub, Leasha J.
    Shah, Bhavin
    Devaraj, Santhana G. T.
    Liu, Ka
    Iyer, Swaminathan
    Bradner, James E.
    Bhalla, Kapil N.
    CANCER RESEARCH, 2014, 74 (19)
12345